文献速递肝病

慢性肝病患者接种SARS-CoV-2疫苗的安全性和免疫原性(CHESS-NMCID 2101):一项多中心研究

Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-12-20

这项前瞻性多中心开放标签研究纳入中国15个中心的581名参与者(437例慢性肝病患者和144名健康志愿者),均接种2剂灭活全病毒SARS-CoV-2疫苗。慢性肝病患者接种后免疫应答低于健康人群,但安全性良好。

要点

  • 慢性肝病患者接种灭活全病毒SARS-CoV-2疫苗后安全性良好,不良反应多为轻度且短暂。
  • 慢性肝病患者SARS-CoV-2中和抗体阳性率低于健康对照(90.3%),差异有统计学意义(P = .008)。
  • 非肝硬化、代偿期肝硬化和失代偿期肝硬化三个亚组的中和抗体阳性率相似(P = .894)。

核心结论

  • 灭活全病毒SARS-CoV-2疫苗在慢性肝病患者中是安全的。
  • 慢性肝病患者对SARS-CoV-2疫苗的免疫应答低于健康人群。
  • 非肝硬化慢性肝病、代偿期肝硬化和失代偿期肝硬化患者的免疫原性同样较低。

研究设计与样本

  • 前瞻性、多中心、开放标签研究,纳入中国15个中心的581名参与者(437例慢性肝病患者和144名健康志愿者)。
  • 所有参与者均接种2剂灭活全病毒SARS-CoV-2疫苗。
  • 在任一次疫苗接种后14天内记录不良反应,第二剂后收集实验室检测结果,第二剂后至少14天采集血清样本检测SARS-CoV-2中和抗体。

主要发现

  • 大多数不良反应为轻度且短暂,注射部位疼痛是最常见的不良事件(n = 36;8.2%)。
  • 3名参与者在第二剂接种后出现3级转氨酶升高(定义为丙氨酸转氨酶>5倍正常上限),其中仅1例被判定为可能与SARS-CoV-2疫苗接种相关的严重不良事件。
  • SARS-CoV-2中和抗体阳性率:非肝硬化慢性肝病组76.8%,代偿期肝硬化组78.9%,失代偿期肝硬化组76.7%(慢性肝病亚组间P = .894),健康对照组90.3%(与慢性肝病组比较P = .008)。

关键数值与推荐

  • 慢性肝病亚组间中和抗体阳性率比较P = .894。
  • 慢性肝病组与健康对照组中和抗体阳性率比较P = .008。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to assess the safety and immunogenicity of inactivated whole-virion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic liver diseases (CLD) in this study. METHODS: This was a prospective, multi-center, open-label study. Participants aged over 18 years with confirmed CLD and healthy volunteers were enrolled. All participants received 2 doses of inactivated whole-virion SARS-CoV-2 vaccines. Adverse reactions were recorded within 14 days after any dose of SARS-CoV-2 vaccine, laboratory testing results were collected after the second dose, and serum samples of enrolled subjects were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose. RESULTS: A total of 581 participants (437 patients with CLD and 144 healthy volunteers) were enrolled from 15 sites in China. Most adverse reactions were mild and transient, and injection site pain (n = 36; 8.2%) was the most frequently reported adverse event. Three participants had grade 3 aminopherase elevation (defined as alanine aminopherase >5 upper limits of normal) after the second dose of inactivated whole-virion SARS-CoV-2 vaccination, and only 1 of them was judged as severe adverse event potentially related to SARS-CoV-2 vaccination. The positive rates of SARS-CoV-2 neutralizing antibodies were 76.8% in the noncirrhotic CLD group, 78.9% in the compensated cirrhotic group, 76.7% in the decompensated cirrhotic group (P = .894 among CLD subgroups), and 90.3% in healthy controls (P = .008 vs CLD group). CONCLUSION: Inactivated whole-virion SARS-CoV-2 vaccines are safe in patients with CLD. Patients with CLD had lower immunologic response to SARS-CoV-2 vaccines than healthy population. The immunogenicity is similarly low in noncirrhotic CLD, compensated cirrhosis, and decompensated cirrhosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ai J, Wang J, Liu D, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. Clin Gastroenterol Hepatol. 2021. PMID: 34942370. doi:10.1016/j.cgh.2021.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。